Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.
Twenty-eight HIV patients either naive or failing highly active antiretroviral therapy (HAART)with moderate-advanced Kaposi's sarcoma (KS)were randomly chosen to initiate a new HAART regimen plus pegylated liposomal doxorubicin(PLD) or the new HAART regimen alone. After 48 weeks, better response rates were observed in the HAART plus PLD group (76% versus 20%). In HIV-infected patients with moderate-advanced KS, HAART alone may not be enough for KS response.
Luz
L
Martin-Carbonero
Ana
A
Barrios
Pere
P
Saballs
Guillem
G
Sirera
Jesus
J
Santos
Rosano
R
Palacios
M Eulalio
ME
Valencia
Marta
M
Alegre
Daniel
D
Podzamczer
Juan
J
González-Lahoz
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D004317:Doxorubicin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin